United States · 
What does Caxton Advantage Life Sciences Fund invest in?
Caxton Advantage Life Sciences Fund invests most often at Series C and Growth (50% of the rounds on record).
Caxton Advantage Life Sciences Fund highlights
- 01
12 rounds on record
- 02
Mostly Series C and Growth: 50% of its rounds
- 03
3 exits from the portfolio
What they do
- Type
- Growth equity (from a list, unverified)
- Cheque size
- Not stated
- Based in
- United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first12 appearances
- 2014
1 round
- Aug
- 2013
1 round
- Jun
- 2012
1 round
- Dec
- 2010
2 rounds
- Aug
- Apr
- 2009
2 rounds
- Dec
- Apr
- 2008
2 rounds
- Aug
- Jul
- 2007
3 rounds
- Dec
- Oct
- Mar
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 1 person at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
Exits from the portfolio
Companies it backed that were later bought or listed3 in all
Gemin X PharmaceuticalsBought by Cephalon$525MMar 2011
Anthera PharmaceuticalsListedUndisclosedMar 2010
An exit counts when it came after the firm's first round in the company. From historical deal records.